Edgewise Therapeutics, Inc. (EWTX)

33.70 +0.54 (+1.63%) USD  |  NASDAQ  |  Apr 15, 16:00
33.21 -0.49 (-1.45%) After-Hours: 20:00
More

Edgewise Therapeutics Research and Development Expense (Annual) : 149.30M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for EWTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Glaukos Corp. 150.61M
Nuvalent, Inc. 306.97M
Boston Scientific Corp. 2.052B
Edwards Lifesciences Corp. 1.079B
Eli Lilly & Co. 13.34B